Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

作者：Lechowicz M J; Lazarus H M; Carreras J; Laport G G; Cutler C S; Wiernik P H; Hale G A; Maharaj D; Gale R P; Rowlings P A; Freytes C O; Miller A M; Vose J M; Maziarz R T; Montoto S; Maloney D G; Hari P N^*

来源：Bone Marrow Transplantation, 2014, 49(11): 1360-1365.

DOI：10.1038/bmt.2014.161

We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P = 0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12-27%) and 22% (95% CI 15-31%), respectively. Risk of disease progression was 50% (95% CI 41-60%) at 1 year and 61% (95% CI 50-71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22-40%) and 17% (95% CI 9-26%), respectively. OS at 1 and 5 years was 54% (95% CI 45-63%) and 32% (95% CI 22-44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.

• 出版日期2014-11